240 related articles for article (PubMed ID: 31719645)
1. Calculation of absolute binding free energies between the hERG channel and structurally diverse drugs.
Negami T; Araki M; Okuno Y; Terada T
Sci Rep; 2019 Nov; 9(1):16586. PubMed ID: 31719645
[TBL] [Abstract][Full Text] [Related]
2. Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
Zachariae U; Giordanetto F; Leach AG
J Med Chem; 2009 Jul; 52(14):4266-76. PubMed ID: 19534531
[TBL] [Abstract][Full Text] [Related]
3. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
[TBL] [Abstract][Full Text] [Related]
4. A critical assessment of combined ligand- and structure-based approaches to HERG channel blocker modeling.
Du-Cuny L; Chen L; Zhang S
J Chem Inf Model; 2011 Nov; 51(11):2948-60. PubMed ID: 21902220
[TBL] [Abstract][Full Text] [Related]
5. In silico analysis of conformational changes induced by mutation of aromatic binding residues: consequences for drug binding in the hERG K+ channel.
Knape K; Linder T; Wolschann P; Beyer A; Stary-Weinzinger A
PLoS One; 2011; 6(12):e28778. PubMed ID: 22194911
[TBL] [Abstract][Full Text] [Related]
6. Interaction simulation of hERG K+ channel with its specific BeKm-1 peptide: insights into the selectivity of molecular recognition.
Yi H; Cao Z; Yin S; Dai C; Wu Y; Li W
J Proteome Res; 2007 Feb; 6(2):611-20. PubMed ID: 17269718
[TBL] [Abstract][Full Text] [Related]
7. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
Thomas D; Karle CA; Kiehn J
Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
[TBL] [Abstract][Full Text] [Related]
8. An automated docking protocol for hERG channel blockers.
Di Martino GP; Masetti M; Ceccarini L; Cavalli A; Recanatini M
J Chem Inf Model; 2013 Jan; 53(1):159-75. PubMed ID: 23259741
[TBL] [Abstract][Full Text] [Related]
9. Molecular docking and molecular dynamics studies on the structure-activity relationship of fluoroquinolone for the HERG channel.
Luo F; Gu J; Chen L; Xu X
Mol Biosyst; 2014 Nov; 10(11):2863-9. PubMed ID: 25100024
[TBL] [Abstract][Full Text] [Related]
10. A novel structure-based virtual screening model for the hERG channel blockers.
Du L; Li M; You Q; Xia L
Biochem Biophys Res Commun; 2007 Apr; 355(4):889-94. PubMed ID: 17331468
[TBL] [Abstract][Full Text] [Related]
11. Block of the hERG channel by bupivacaine: Electrophysiological and modeling insights towards stereochemical optimization.
Sintra Grilo L; Carrupt PA; Abriel H; Daina A
Eur J Med Chem; 2011 Aug; 46(8):3486-98. PubMed ID: 21624711
[TBL] [Abstract][Full Text] [Related]
12. In silico predictions of hERG channel blockers in drug discovery: from ligand-based and target-based approaches to systems chemical biology.
Taboureau O; Jørgensen FS
Comb Chem High Throughput Screen; 2011 Jun; 14(5):375-87. PubMed ID: 21470179
[TBL] [Abstract][Full Text] [Related]
13. Stereoselective block of hERG channel by bupivacaine scrutinized at molecular level.
Grilo LS; Carrupt PA; Daina A
Chimia (Aarau); 2010; 64(3):165-9. PubMed ID: 21140912
[TBL] [Abstract][Full Text] [Related]
14. Dynamics of hERG closure allow novel insights into hERG blocking by small molecules.
Schmidtke P; Ciantar M; Theret I; Ducrot P
J Chem Inf Model; 2014 Aug; 54(8):2320-33. PubMed ID: 25000969
[TBL] [Abstract][Full Text] [Related]
15. Revealing the structural basis of action of hERG potassium channel activators and blockers.
Perry M; Sanguinetti M; Mitcheson J
J Physiol; 2010 Sep; 588(Pt 17):3157-67. PubMed ID: 20643767
[TBL] [Abstract][Full Text] [Related]
16. The molecular determinants of R-roscovitine block of hERG channels.
Cernuda B; Fernandes CT; Allam SM; Orzillo M; Suppa G; Chia Chang Z; Athanasopoulos D; Buraei Z
PLoS One; 2019; 14(9):e0217733. PubMed ID: 31479461
[TBL] [Abstract][Full Text] [Related]
17. Computer simulations of structure-activity relationships for HERG channel blockers.
Boukharta L; Keränen H; Stary-Weinzinger A; Wallin G; de Groot BL; Aqvist J
Biochemistry; 2011 Jul; 50(27):6146-56. PubMed ID: 21657256
[TBL] [Abstract][Full Text] [Related]
18. Assessing hERG pore models as templates for drug docking using published experimental constraints: the inactivated state in the context of drug block.
Dempsey CE; Wright D; Colenso CK; Sessions RB; Hancox JC
J Chem Inf Model; 2014 Feb; 54(2):601-12. PubMed ID: 24471705
[TBL] [Abstract][Full Text] [Related]
19. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
Durdagi S; Duff HJ; Noskov SY
J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
[TBL] [Abstract][Full Text] [Related]
20. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers.
Aronov AM
J Med Chem; 2006 Nov; 49(23):6917-21. PubMed ID: 17154521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
